title: [Clinical applications of dosing algorithm in the predication of warfarin maintenance dose].
abstract: OBJECTIVE
  To evaluate the feasibility of clinical application for genetic based dosing algorithm in the predication of warfarin maintenance dose in Chinese population.
  
  
  METHODS
  The clinical data were collected and blood samples harvested from a total of 126 patients undergoing heart valve replacement. The genotypes of VKORC1 and CYP2C9 were determined by melting curve analysis after PCR. They were divided randomly into the study and control groups. In the study group, the first three doses of warfarin were prescribed according to the predicted warfarin maintenance dose while warfarin was initiated at 2.5 mg/d in the control group. The warfarin doses were adjusted according to the measured international normalized ratio (INR) values. And all subjects were followed for 50 days after an initiation of warfarin therapy.
  
  
  RESULTS
  At the end of a 50-day follow-up period, the proportions of the patients on a stable dose were 82.4% (42/51) and 62.5% (30/48) for the study and control groups respectively. The mean durations of reaching a stable dose of warfarin were (27.5 ± 1.8) and (34.7 ± 1.8) days and the median durations were (24.0 ± 1.7) and (33.0 ± 4.5) days in the study and control groups respectively. Significant differences existed in the durations of reaching a stable dose between the two groups (P = 0.012). Compared with the control group, the hazard ratio (HR) for the duration of reaching a stable dose was 1.786 in the study group (95%CI 1.088 - 2.875, P = 0.026).
  
  
  CONCLUSIONS
  The predicted dosing algorithm incorporating genetic and non-genetic factors may shorten the duration of achieving efficiently a stable dose of warfarin. And the present study validates the feasibility of its clinical application.
authors.affiliation: Department of Laboratory Medicine, Guizhou Provincial People's Hospital, Guiyang, China. hsw713@sina.com
authors.forename: Sheng-wen
authors.initials: SW
authors.lastname: Huang
authors.forename: Dao-kang
authors.initials: DK
authors.lastname: Xiang
authors.forename: Bang-quan
authors.initials: BQ
authors.lastname: An
authors.forename: Gui-fang
authors.initials: GF
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Huang
authors.forename: Hai-li
authors.initials: HL
authors.lastname: Wu
mesh_terms: D000328:Adult; D000465:Algorithms; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D014859:Warfarin / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D014859:Warfarin